Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Efficacy of zinc in common cold - Review of clinical trials

A new study has added to the existing literature that debates the role of zinc in combating the common cold. It suggests that the supplement might modestly reduce cold duration and severity or maybe even prevent it. The report was published as a Cochrane Review.

15 Feb 2011

Zinc supplements reduce burden of common cold

Zinc supplements reduce the severity and duration of illness caused by the common cold, according to a systematic review published in The Cochrane Library. The findings could help reduce the amount of time lost from work and school due to colds.

15 Feb 2011

Molecular helper Spy aids designer bacteria to produce large quantities of stable, functional proteins

Scientists have discovered a molecular assistant called Spy that helps bacteria excel at producing proteins for medical and industrial purposes.

15 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

First evidence of human DNA fragment in bacterial genome

If a human cell and a bacterial cell met at a speed-dating event, they would never be expected to exchange phone numbers, much less genetic material. In more scientific terms, a direct transfer of DNA has never been recorded from humans to bacteria.

14 Feb 2011

Optimer prices underwritten public offering of common stock

Optimer Pharmaceuticals, Inc. today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share. The gross proceeds to Optimer from this offering are expected to be $67.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Optimer.

11 Feb 2011

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Anacor Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

11 Feb 2011

£160,000 award to devise anti-microbial collar to prevent bacterial infections associated with broken bones

Orthopaedic experts at The University of Nottingham are hoping to reduce the rate of infections that often occur in the pinning of broken bones by developing a special collar to counter dangerous microbes.

11 Feb 2011

Global Hygiene Council: Three simple steps to keep your family protected against infections

The Global Hygiene Council, a group of leading health and hygiene experts from around the world, convened in collaboration with the Centers for Disease Control and Prevention to discuss how proper hygiene plays a critical role in preventing the spread of illness and improving health around the world.

10 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Life Sciences Discovery Fund announces nearly $600,000 in awards

The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.

9 Feb 2011

Drugs against protective action of bacteria's antitoxin molecules

Bacteria often attack with toxins designed to hijack or even kill host cells. To avoid self-destruction, bacteria have ways of protecting themselves from their own toxins.

9 Feb 2011

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

Abbott's Ibis, PLEX-ID technologies identify causative organism of plague in Afghanistan

Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the unique power of the company's Ibis technology to identify and further characterize unknown disease-causing pathogens to help aid in the bioforensic analysis of pandemic outbreaks.

8 Feb 2011

Abbott launches PLEX-ID Biothreat Assay to detect, distinguish 17 different pathogens

Abbott announced today that it has introduced the PLEX-ID Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens.

7 Feb 2011

Dermatologists urge athletes to be aware of most common skin infections

Team sports have a long history of fostering cooperation, camaraderie and a healthy competitive spirit among athletes. But the closeness that brings athletes together also can create an environment for a host of contagious skin infections. Now, dermatologists are urging teammates and coaches to be aware of the most common skin conditions caused by bacteria, viruses and fungi that occur in athletes and educating them on how to prevent a widespread outbreak.

5 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

Antibiotic News and Research

Further Reading

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Efficacy of zinc in common cold - Review of clinical trials

Zinc supplements reduce burden of common cold

Molecular helper Spy aids designer bacteria to produce large quantities of stable, functional proteins

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

First evidence of human DNA fragment in bacterial genome

Optimer prices underwritten public offering of common stock

RF-induced heat therapy could help treat common parasitic skin infection

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

£160,000 award to devise anti-microbial collar to prevent bacterial infections associated with broken bones

Global Hygiene Council: Three simple steps to keep your family protected against infections

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Life Sciences Discovery Fund announces nearly $600,000 in awards

Drugs against protective action of bacteria's antitoxin molecules

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Abbott's Ibis, PLEX-ID technologies identify causative organism of plague in Afghanistan

Abbott launches PLEX-ID Biothreat Assay to detect, distinguish 17 different pathogens

Dermatologists urge athletes to be aware of most common skin infections

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News